Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harte Hanks (HHS) EBITDA (2016 - 2025)

Harte Hanks (HHS) has disclosed EBITDA for 16 consecutive years, with -$218000.0 as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA fell 275.86% to -$218000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $3.0 million, a 302.38% increase, with the full-year FY2024 number at $196000.0, down 92.58% from a year prior.
  • EBITDA was -$218000.0 for Q2 2025 at Harte Hanks, down from $378000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $30.6 million in Q4 2022 to a low of -$1.5 million in Q1 2021.
  • A 5-year average of $4.7 million and a median of $2.1 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 3330.77% in 2021, then plummeted 275.86% in 2025.
  • Harte Hanks' EBITDA stood at $13.3 million in 2021, then surged by 130.47% to $30.6 million in 2022, then tumbled by 102.71% to -$831000.0 in 2023, then skyrocketed by 145.49% to $378000.0 in 2024, then crashed by 157.67% to -$218000.0 in 2025.
  • Per Business Quant, the three most recent readings for HHS's EBITDA are -$218000.0 (Q2 2025), $378000.0 (Q4 2024), and $2.9 million (Q3 2024).